Teleflex (TFX) Jefferies London Healthcare Conference 2024 summary

Business positioning and market environment

• Focuses on critical care, with stable procedure volumes in hospitals and emergency care settings.

• Key growth areas include interventional access, rectal spacing for prostate cancer, and large bore closure.

• Geographic revenue split: 23% Europe, 12% Asia Pacific, with ongoing expansion in both regions.

• U.S. and international markets remain stable, with robust procedure environments and selective growth in Asia.

• Product launches and portfolio performance are strong in high-growth European and Asian markets.

Capital allocation and M&A strategy

• Generates robust cash flow, with $500M from operations and $400M net cash flow expected this year.

• Prioritizes internal investment, strategic M&A, and shareholder returns, including a $500M share repurchase plan.

• Targets M&A within existing verticals, seeking assets that accelerate top-line growth and enhance margins.

• Recent acquisitions include MANTA, Z-Medica, HPC, Titan stapler, and Palette Life Sciences, with disciplined cadence.

• Plans to methodically utilize the remaining $300M of the share repurchase program.

Growth portfolio and financial outlook

• High growth portfolio targets 12–13% growth, with strong performance from Barrigel, PICC, Z-Medica, and MANTA.

• Durable core (two-thirds of business) grows at 5%, with stable performance and opportunities in Asia Pacific.

• Three-year plan (2023–2025) aims for 6% revenue CAGR, 250 bps gross margin expansion, and 200 bps operating margin improvement.

• 2023 revenue growth exceeded targets; 2024 slightly below, with margin progress ongoing despite inflation.